Overview


According to FutureWise analysis the market for primary hepatocytes in 2023 is US$ 0.24 billion, and is expected to reach US$ 0.41 billion by 2031 at a CAGR of 6.8%.

Primary hepatocytes are hepatocytes that have been separated directly from liver tissue. A schematic of the technique for isolating primary human hepatocytes, as well as their cellular morphology in suspension and on plates, is shown on the left side. Hepatocytes are frequently used to evaluate potential drug candidates, allowing researchers to move novel treatments into clinical trials faster. Developing novel drug therapies that meet the needs of patients and clinicians is a huge undertaking, one whose success is largely determined by the accuracy of the models employed in testing. Animal models will become less necessary as technology advances, with increasingly in vivo-like systems taking their place. As a result, demand for primary hepatocytes will rise over the anticipated time. The number of cancer patients is increasing, as is the demand for cancer treatment. As a result, primary hepatocyte research is becoming more popular. By allowing each patient to receive an earlier diagnosis, risk assessment, and optimal therapy, personalised medicine gives the best response and safety margin to provide improved patient care. These tailored drugs are created in laboratories utilising primary hepatocytes. The desire for tailored therapies has fueled the growth of the primary hepatocyte market. Additional approaches, such as hepatocyte transplantation, have been investigated to compensate for the lack of liver donors. This will boost demand for primary hepatocytes right away, propelling market growth.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Primary Hepatocytes Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Primary Hepatocytes Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Thermo Fisher Scientific
  • Corning Inc.
  • Lonza
  • Axol Bioscience Ltd.
  • LifeNet Health
  • SEKISUI XenoTech, LLC.
  • Cytes Biotechnologies
  • Cell Biologics, Inc.
  • ZenBio, Inc.
  • BioIVT.
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Takara Bio Inc.
  • Kosheeka

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species

  • Humans
  • Rats
  • Mice
  • Dogs
  • Monkeys
  • Horses
  • Others

By Application

  • Cell Viability Assays
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assays
  • In Vitro Intrinsic Clearance
  • Phospholipoids Assays
  • Others

By End User

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Primary Hepatocytes Market By Product, By Species, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Primary Hepatocytes Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Primary Hepatocytes Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Primary Hepatocytes Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Primary Hepatocytes Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cryopreserved Suspension Hepatocytes
        2. Fresh Suspension Hepatocytes
        3. 3D (Spheroid) Hepatocytes
        4. Expanded Hepatocytes (Plateable)
        5. Non-characterized Hepatocytes

  • 8.   Primary Hepatocytes Market, By Species Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Humans
        2. Rats
        3. Mice
        4. Dogs
        5. Monkeys
        6. Horses
        7. Others

  • 9.   Primary Hepatocytes Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cell Viability Assays
        2. Cytochrome Enzyme Activity
        3. High Content Cytotoxicity
        4. Transporter Inhibition Assays
        5. In Vitro Intrinsic Clearance
        6. Phospholipoids Assays
        7. Others

  • 10.   Primary Hepatocytes Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Biopharmaceutical Companies
        2. Academic and Research Institutes
        3. Contract Research Organizations

  • 11.   North America Primary Hepatocytes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Primary Hepatocytes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Primary Hepatocytes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Primary Hepatocytes Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Corning Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Lonza
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Axol Bioscience Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. LifeNet Health
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. SEKISUI XenoTech, LLC.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cytes Biotechnologies
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Cell Biologics, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. ZenBio, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. BioIVT.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. ScienCell Research Laboratories, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Kerafast
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Takara Bio Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Kosheeka
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients